MS and the Holy Grail of MS Neural Repair
A couple of days ago I got the latest edition of MS Focus Magazine. I found two paragraphs that brought me renewed hope for an effective treatment for MS. They are reprinted below.
Medicine & Research:
Of a slightly different mechanism than the previously mentioned monoclonal antibodies, temelimab targets a specific protein that is believed to have a role in the development of MS. MS is caused in part by increased inflammation in the central nervous system, and the intended mechanism of action for temelimab would be to relieve this inflammation to prevent progression. The medication should work to help fix the damage to the myelin sheath that occurs in MS.
By Ellen Whipple, Pharm.D.
Life with MS:
The Holy Grail of MS care is neural repair. By repairing areas of damaged myelin and axons or rerouting information around areas of damage, the hope is that we may be able to reverse disability. Numerous research projects around the world are focusing on this. It could be that the answer to reversing disability ends up coming from a non-MS field, such as spinal cord injury. Currently, phase II studies are ongoing with a molecule I’m excited about, elezanumab. If this monoclonal antibody does what we hope it will, it should regenerate axons in the brain and spinal cord.
By Dr. Ben Thrower, M.D.
It is this second paragraph that excites me the most. If it works, you would still have MS. But the chances are you wouldn’t experience any, or at least not as sever, symptoms as many of us currently suffer from. There is hope on the horizon!